Molecular basis of thrombophilia

Journal of Medical Biochemistry

Volumn 33, Issue 1, 2014, Pages 22-27

  Dordević, Valentina ^a   Pruner, Iva ^a   Radojković, Dragica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Gene variants; Genetic risk factors; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; ANTITHROMBIN III; ARGININE; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CYTOCHROME P450 2C9; FIBRINOGEN; FIBRINOGEN GAMMA GAMMA; GLUTAMINE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VON WILLEBRAND FACTOR;

3' UNTRANSLATED REGION; ACTIVATED PROTEIN C RESISTANCE; AMINO ACID SUBSTITUTION; ANTITHROMBIN DEFICIENCY; ANTITHROMBIN DEFICIENCY TYPE I; ANTITHROMBIN DEFICIENCY TYPE II; ANTITHROMBIN RESISTANCE; BLOOD GROUP A; BLOOD GROUP A1; BLOOD GROUP B; ENVIRONMENTAL FACTOR; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; PATHOGENESIS; PERSONALIZED MEDICINE; POINT MUTATION; POLYADENYLATION; PREDICTION; PROMOTER REGION; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOPHILIA;

EID: 84903312739     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/jomb-2013-0037     Document Type: Review

References (52)

1. Colman RW, Clowes AW, George JN, Goldhaber SZ, Marder VJ. Overview of hemostasis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ. Hemostasis and Thrombosis: basic principles and clinical practice. 5th ed. Philadelphia: Lippencott Wiliams and Wilkins, 2006:2-15.
2. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65.
3. Ruggeri ZM. Mechanisms Initiating Platelet Thrombus Formation. Thromb Haemost 1997;78:611-16.
4. Saito H, Takamatsu J. Disorders of Prothrombin Conversion. In: Gross S, Roarh S, editors. Hematology: A problem-oriented approach. Baltimor: Williams and Wilkins, 2000:570-1.
5. Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M. Newer concepts of blood coagulation. Haemophilia 1998;4:331-4.
6. Dang QD, Vindigni A, Dicera E. An allosteric switch controls the procoagulant and anticoagulant activites of thrombin. Proc Natl Acad Sci USA 1995;92:5977-81.
7. Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, Rumennik G, Seto M, et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000;404:518-25.
8. Degen JL. Genetic interaction between the coagulation and fibrinolytic system. Thromb Haemost 2001;86:30-7.
9. Elezović I. Urodene i stečene trombofilije. Bilten za transfuziologiju 2000; Suppl 1:16-25.
10. Heit JA. The epidemiology of venous thromboembolism in the community. Arteriosder Thromb Vase Biol 2008;28:370-2.
11. Lowe GD. Common risk factors for both arterial and venous thrombosis. Br J Haematol 2008;140:488-95.
12. Jordan FL, Nandorff A. The familial tendency in thromboembolic disease. Acta Med Scand 1956;156:267-75.
13. Marz W, Nauck M, Wieland H. The molecular mechanisms of inherited thrombophilia. Z Kardiol 2000;89:575-86.
14. Rosendaal FR, Reitisma PH. Genetic of venous thrombosis. J Thromb Haemost 2009;7:301-4.
15. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-30.
16. Cooper PC, Coath F, Daly ME, Makris M. The phenotypic and genetic assessment of antithrombin deficiency. Int J Lab Hematol 2011;33:227-37.
17. Bucciarelli P, Passamonti SM, Biguzzi E, Gianniello F, Franchi F, Mannucci PM, et al. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J Thromb Haemost 2012;10:1783-91.
18. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-31.
19. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Investig 1981;68:1370-3.
20. Van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am 1998;12:1141-66.
21. Comp PC, Esmon CT Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984;311:1525-8.
22. Beauchamp NJ, Dykes AC, Parikh N, Campbell Tait R, Daly ME. The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haematol 2004;125:647-54.
23. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
24. Bertina RM, Koeleman B P C, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-6.
25. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
26. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
27. Bertina RM. Genetic approach to thrombophilia. Thromb Heamost 2001;86:92-103.
28. Danckwardt S, Hartmann K, Gehring NH, Hentze MW, Kulozik AE. 3' end processing of the prothrombin mRNA in thrombophilia. Acta Haematol 2006;115:192-7.
29. Dordević V, Pruner I, Kovač M, Miljić P, Antonijević N, Kojić S, Radojković D. Three novel 3'end prothrombin gene polymorphisms and their association with thrombophilia (abstract). J Thromb Haemost 2012;9: Suppl 2:873.
30. Danckwardt S, Gehring NH, Neu-Yilik G, Hundsdoerfer R Pforsich M, Frede U, Hentze MW, Kulozik AE. The prothrombin 3'end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood 2004;104:428-35.
31. Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012;366:2390-6.
32. Dordević V, Kovač M, Pruner I, Francuski D, Radojković D. A novel prothrombin c.1787G>A mutation in a Serbian family with recurrent thromboembolism - anothser case of antithrombin resistance (abstract). J Thromb Haemost 2013;11:375.
33. Uitte De Willige S, De Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005;106:4176-83.
34. Chung DW, Davie EW. Gamma and gamma' chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984;23:4232-6.
35. Eriksson R Kallin B, Van't Hofft FM, Bćvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-5.
36. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides R Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 2008;122:736-42.
37. Jick H, Slone D, Westerholm B, Inman WH, Vessey MR Shapiro S, et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969;1:539-42.
38. Wu O, Bayoumi N, Vickers MA, Clark R ABO (H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008;6:62-9.
39. Tregouet DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009;113:5298-303.
40. McGrath RT, McKinnon TA, Byrne B, O'Kennedy R, Terraube V, McRae E, et al. Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood 2010;115:2666-73.
41. Ohira T, Cushman M, Tsai MY, Zhang Y, Heckbert SR, Zakai NA, et al. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2007;5:1455-61.
42. Cohen W, Castelli C, Alessi MC, Aillaud MF, Bouvet S, Saut N, et al. ABO blood group and von Willebrand factor levels partially explained the incomplete penetrance of congenital thrombophilia. Arteriosder Thromb Vase Biol 2012;32:2021-8.
43. Koster T, Blann AD, Briet E, Vandenbroucke IP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995;345:152-5.
44. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-62.
45. Li C, Schwarz Ul, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009;113:3925-30.
46. Daly A. Pharmacogenomics of anticoagulants: steps toward personal dosage. Genom Med 2009;1:10.
47. Babić N. Clinical pharmacogenomics and concept of personalized medicine. J Med Biochem 2012;31:281-6.
48. *3 genotypes. Thromb Thrombolysis 2011;32:368-71
49. Antonijević N, Stanojević M, Milošević R, Dordević V, Jauković M, Vukčević V, et al. Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirtythree-year follow-up. J Thromb Thrombolysis 2005;19:93-5.
50. De Haan HG, Bezemer ID, Doggen G, Le Cessie S, Reitsma PH, Arellano AR, et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 2012;120:656-63.
51. Ocak G, Vossen CY, Verduijn M', Dekker FW, Rosendaal FR, Cannegieter SC, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost 2013;11:116-23.
52. Bezemer ID, Bare LA, Doggen G, Arellano AR, Tong C, Rowland CM, et al. Gene variants associated with deep vein thrombosis. JAMA 2008;299:1306-14.